Portfolio News

Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced topline results from its 28-week Phase 2b study of lenabasum in patients with cystic fibrosis (CF). The study enrolled patients in the U.S., Canada and Europe at high risk for recurrent pulmonary exacerbations (PEx). Subjects received lenabasum or placebo added to their background treatments for CF. Read more >>
Read more...

Elite Athletes Use ZetrOZ Systems’ sam® Technology to Heal Quicker and Avoid Surgery

sam® ultrasound, ZetrOZ Systems' sustained acoustic medicine device, is the preferred healing solution of countless professional and collegiate athletes. The wearable, long-duration ultrasound technology helps athletes avoid surgery while accelerating natural healing, proving to be extremely valuable in cases of acute and chronic pain, especially those that involve soft tissue damage. Read more >>
Read more...

Oncocyte Agrees to Enter Licensing and Collaboration Agreement with Chronix Biomedical

Oncocyte Corporation, a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has agreed to enter a licensing and collaboration agreement with Chronix Biomedical. Oncocyte is licensing Chronix’s patented CNI Monitor technology for the TheraSure™-CNI MONITOR clinical assay. Read more >>
Read more...

XYLYX BIO launches specialized contract R&D services that increase predictiveness in antifibrotic drug discovery

Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug discovery paradigm is highly inefficient. Read more >>
Read more...

The 100 People You Don’t Know But Should 2020

Sue Nolin VP, Inside Sales, Wasabi Technologies -- When it comes to growing sales and its channel team, Wasabi turns to Nolin. She is constantly working to up the cloud storage vendor’s game when it comes to supporting solution providers’ sales efforts every day. She knows the channel is key to her and Wasabi’s success. Read more >>
Read more...

Cognoptix Revitalizes, Appoints New Chief Executive Officer Dr. Susanne Wilke, PhD, Raises Oversubscribed $2.6m Series R

Cognoptix, a healthcare company developing the Sapphire II System, a breakthrough technology for early detection of Alzheimer's disease (AD), announces the closing of an over-subscribed Series R financing round. Cognoptix has undergone a complete revitalization over the past year. Read more >>
Read more...

Seattle gene therapy biotech startup Immusoft raises $4.5M

Seattle-based biotech startup Immusoft raised another $4.5 million and landed a $467,000 NIH grant to help further development of its drugs that treat genetic diseases. Founded in 2009, Immusoft develops immune cell technology that uses blood cells from a patient to create therapeutic proteins targeted to treat diseases. Its lead candidate, ISP-001, treats Mucopolysaccharidosis type I, or MPS I, and has both orphan drug and rare pediatric disease designations from the FDA. Read more >>
Read more...